Moreover, ctDNA analysis was able to detect additional KRAS and NRAS mutations that were not detected by conventional tumor tissue analysis, and the cases with newly detected RAS mutations showed poor response to cetuximab-containing chemotherapy. The gene discussed is NRAS; the disease is neoplasm.